Author’s response to reviews

Title: Antimicrobial activity of amlodipine against extensively drug-resistant Acinetobacter baumannii isolates in vitro

Authors:

Yu jun Li Dr (liyujun_0110@163.com)
Chu zhi PAN (fanshusi@163.com)
Zi wen ZHAO (zhaozw@yeah.net)
Zhu xiang ZHAO (zhaozhuxiang@126.com)
Hui ling CHEN (huiling1515@163.com)
Wei bo LU (luweibo-520@163.com)

Version: 3 Date: 20 January 2013

Author’s response to reviews: see over
Dear Editors:

We would like to submit the enclosed manuscript entitled “Antimicrobial activity of amlodipine against extensively drug-resistant Acinetobacter baumannii isolates in vitro”, which we wish to be considered for publication in “BMC Infectious Diseases”.

Acinetobacter baumannii has emerged as one of the most troublesome pathogens for health care institutions globally. It is characterized by frequent multiresistance due to multiple mechanisms, and therapeutic options are becoming increasingly restricted. Although colistin has been used successfully to treat multidrug resistant Acinetobacter baumannii infections in a significant number of patients, due to its unavailability in many countries, carbapenems, such as imipenem, remain the first choice against A. baumannii strains in China. Finding a way to enhance the antibiotic activity (synergism) of carbapenems against A. baumannii strains may be encouraging. Recently, an effective approach has been to explore non-antibiotic compounds (helper compounds) that express antibacterial properties, possibly by acting through different mechanisms from those of existing drugs, either by the enhancement of antibiotic activity (synergism) or reversal of antibiotic resistance, bringing drug-resistant microorganisms back to their original sensitivity to classical antibiotics. Among those non-antibiotics, amlodipine is the most promising helper compound. It has been shown to exhibit in vitro activity against a wide range of bacteria, but few studies have reported its potentiating effect on clinical A. baumannii isolates. In this work, amlodipine was tested alone and in combination with imipenem against A. baumannii isolates, and its potential mechanism of action was explored.

No conflict of interest exits in the submission of this manuscript, and manuscript is approved by all authors for publication. I would like to declare on behalf of my co-authors that the work described was original research that has not been published previously, and not under consideration for publication elsewhere, in whole or in part. All the authors listed have approved the manuscript that is enclosed.

This manuscript has been edited and proofread by American Journal Experts, LLC. I hope this paper is suitable for “BMC Infectious Diseases”. The following is a list of possible reviewers for your consideration:

1) XIONG Jian-hui   E-mail: jh_x0508@163.com

We deeply appreciate your consideration of our manuscript, and we look forward to receiving
comments from the reviewers. If you have any queries, please don’t hesitate to contact me at the address below. Thank you and best regards.

Yours sincerely,

LI Yu-jun

Corresponding author:

Name: ZHAO Zi-wen

E-mail: zhaozw@yeah.net